These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 33691517)

  • 1. Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania.
    Vieta E; Sachs G; Chang D; Hellsten J; Brewer C; Peters-Strickland T; Hefting N
    J Psychopharmacol; 2021 Aug; 35(8):971-982. PubMed ID: 33691517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder.
    Bauer M; Hefting N; Lindsten A; Josiassen MK; Hobart M
    Acta Neuropsychiatr; 2019 Feb; 31(1):27-35. PubMed ID: 30223911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder.
    Hobart M; Zhang P; Skuban A; Brewer C; Hefting N; Sanchez R; McQuade RD
    J Clin Psychopharmacol; 2019; 39(3):203-209. PubMed ID: 30946704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
    McEvoy J; Citrome L
    Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
    Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis.
    Kishi T; Sakuma K; Nomura I; Matsuda Y; Mishima K; Iwata N
    Int J Neuropsychopharmacol; 2019 Nov; 22(11):698-709. PubMed ID: 31350882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study.
    Davis LL; Ota A; Perry P; Tsuneyoshi K; Weiller E; Baker RA
    Brain Behav; 2016 Oct; 6(10):e00520. PubMed ID: 27781135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms:
    Meade N; Shi L; Meehan SR; Weiss C; Ismail Z
    J Psychopharmacol; 2020 Aug; 34(8):829-838. PubMed ID: 32648810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials.
    Grossberg GT; Kohegyi E; Mergel V; Josiassen MK; Meulien D; Hobart M; Slomkowski M; Baker RA; McQuade RD; Cummings JL
    Am J Geriatr Psychiatry; 2020 Apr; 28(4):383-400. PubMed ID: 31708380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
    Fava M; Ménard F; Davidsen CK; Baker RA
    J Clin Psychiatry; 2016 Dec; 77(12):1695-1701. PubMed ID: 27379823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
    Hobart M; Skuban A; Zhang P; Josiassen MK; Hefting N; Augustine C; Brewer C; Sanchez R; McQuade RD
    Curr Med Res Opin; 2018 Apr; 34(4):633-642. PubMed ID: 29343128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania.
    Milienne-Petiot M; Geyer MA; Arnt J; Young JW
    Psychopharmacology (Berl); 2017 Mar; 234(6):1017-1028. PubMed ID: 28160035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study.
    Calabrese JR; Keck PE; Starace A; Lu K; Ruth A; Laszlovszky I; Németh G; Durgam S
    J Clin Psychiatry; 2015 Mar; 76(3):284-92. PubMed ID: 25562205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brexpiprazole: a new leaf on the partial dopamine agonist branch.
    Hope J; Castle D; Keks NA
    Australas Psychiatry; 2018 Feb; 26(1):92-94. PubMed ID: 29017334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.
    Kane JM; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    Schizophr Res; 2015 May; 164(1-3):127-35. PubMed ID: 25682550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Brexpiprazole on Agitation and Hostility in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies.
    Citrome L; Ouyang J; Shi L; Meehan SR; Baker RA; Weiss C
    J Clin Psychopharmacol; 2019; 39(6):597-603. PubMed ID: 31652166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies.
    Correll CU; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Kane JM
    Schizophr Res; 2016 Jul; 174(1-3):82-92. PubMed ID: 27157799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Correll CU; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    Am J Psychiatry; 2015 Sep; 172(9):870-80. PubMed ID: 25882325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.